pamidronate disodium / Generic mfg. - LARVOL DELTA

Injectable hydrogel induces tumor cell extracellular calcification and bone regeneration to disrupt the osteolytic vicious cycle in bone metastasis. (PubMed, J Control Release) - "Pamidronate (APD), a nitrogen-containing bisphosphonate, has shown potential in managing osteolytic lesions by inhibiting osteoclast activity...Moreover, CHA exhibited excellent biocompatibility with no observed systemic toxicity. These results underscore the promise of CHA as a clinically translatable therapeutic strategy for the treatment of osteolytic bone metastases."

Journal • Breast Cancer • Oncology • Solid Tumor • PTHLH • RUNX2

Chronic non-bacterial osteitis/osteomyelitis (CNO) in adolescence : A therapeutic challenge in rheumatology (PubMed, Z Rheumatol) - "The implementation of regular reevaluations-including magnetic resonance imaging (MRI) if necessary-is essential for the desired treat-to-target strategy. The patient care should be carried out in centers with an interdisciplinary approach and experience in the treatment of CNO."

Journal • Inflammation • Rheumatology

Novel use of bisphosphonates to improve surgical outcomes in experimental bone tuberculosis. (PubMed, World J Orthop) - "A single intravenous dose of pamidronate significantly enhances bone regeneration and prevents implant resorption following surgical treatment of tuberculous osteitis. The following prospective studies are needed."

Journal • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Exploring Molecular Signature and Prognostic Biomarkers in Ovarian Cancer: Insights From Late-Stage, Recurrent, and Metastatic Tumors. (PubMed, Biotechnol Appl Biochem) - "Ocriplasmin and pamidronate were identified as potential therapeutics. Our findings highlight the therapeutic relevance of these hub genes and identify them as potential drug targets and prognostic biomarkers in ovarian cancer."

Biomarker • Journal • Oncology • Ovarian Cancer • Solid Tumor • COL1A1 • COL1A2 • COL3A1 • CXCL8 • FN1 • IGF1 • MIR29A • POSTN

Retrospective Analysis of Ambulatory Children with Osteogenesis Imperfecta Demonstrates Increased Fracture Rate and Reduced Bone Density During the COVID-19 Pandemic (ACMG 2026) - "Eight received pamidronate from 2019 to 2021 (9mg/kg/year, n=2; 4.5mg/kg/year, n=6)... The social restrictions during the pandemic were associated with decreased LS BMD and increased fracture incidence that improved when restrictions were lifted. There was sustained increased adiposity in this group of children with OI. These results suggest that children with OI were negatively impacted by restrictions during the pandemic"

Retrospective data • Genetic Disorders • Infectious Disease • Musculoskeletal Diseases • Novel Coronavirus Disease • Obesity • Orthopedics

Is Parenteral Bisphosphonate Therapy Safe and Effective in the Management of Severe Primary Hyperparathyroidism Prior to Parathyroidectomy? (PubMed, Clin Endocrinol (Oxf)) - "We review the limited evidence around preoperative bisphosphonate administration in patients with hyperparathyroid crisis and examine the efficacy and safety of intravenous pamidronate in our own patient series. Whilst the management remains largely empirical, we suggest that bisphosphonates can be considered to safely facilitate parathyroidectomy, since intravenous fluid therapy alone is often insufficient to control severe hypercalcaemia. Preoperative calcium optimisation that includes intravenous bisphosphonate therapy should be prioritised over the theoretical risk of aggravating postoperative hypocalcaemia; the latter of which may be ameliorated by adequate preoperative vitamin D replacement."

Journal • Endocrine Disorders

Repurposing osteoporosis medications for other diseases: a narrative review by the European Calcified Tissue Society (ECTS). (PubMed, Bone) - "Repurposing osteoporosis medications represents a cost-effective, timely strategy to expand treatment options across diverse clinical indications. While promising outcomes have been demonstrated-particularly in rare diseases-rigorous, indication-specific clinical trials are essential to confirm efficacy, safety, and long-term outcomes. The accumulated pharmacologic and clinical experience with these agents offers a strong foundation for their continued exploration beyond osteoporosis."

Journal • Review • Endocrine Disorders • Hypoparathyroidism • Immunology • Langerhans Cell Histiocytosis • Musculoskeletal Pain • Osteoarthritis • Osteoporosis • Pain • Rare Diseases • Rheumatoid Arthritis • Rheumatology

Effectiveness of treatments to prevent femoral periprosthetic bone loss following total hip arthroplasty: a network meta-analysis. (PubMed, Front Pharmacol) - "At 6 months, alendronate, alendronate + alfacalcidol, denosumab, ibandronate, raloxifene, teriparatide + alendronate, and zoledronic acid were beneficial in increasing BMD, with denosumab ranking highest (based on surface under the cumulative ranking curve (SUCRA) values). At 12 months, alendronate, alendronate + alfacalcidol, denosumab, ibandronate, risedronate, and zoledronic acid showed benefits, with alendronate + alfacalcidol ranking highest (SUCRA = 0.97)...Analysis of BMD at 5-10 years, involving four studies on alendronate, pamidronate, and placebo, indicated that alendronate achieved the highest SUCRA value (0.87)...Denosumab was the most efficient agent for increasing BMD at 6 months post-THA, while alendronate combined with alfacalcidol or feriparatide was most efficient at 12 months and 24 months. More high-quality direct comparisons and long-term follow-up studies are needed to determine the optimal drug and dosage for THA..."

Journal • Retrospective data • Orthopedics • Osteoporosis • Rheumatology

Clinical Outcome of Patients with Osteogenesis Imperfecta on Intravenous Pamidronate Treatment at the Philippine General Hospital from 2010-2018. (PubMed, Acta Med Philipp) - "However, the difference is not statistically significant. Cyclic intravenous pamidronate treatment in young children with moderate-severe OI is well tolerated and associated with reduced fracture frequency with a tendency to improvement of gross functional mobility."

Clinical data • Journal • Genetic Disorders • Musculoskeletal Diseases • Orthopedics • Rheumatology

Efficacy and Safety of Bisphosphonates for Complex Regional Pain Syndrome : A Systematic Review and Meta-analysis. (PubMed, Ann Intern Med) - "Eleven trials (754 participants; CRPS type I, 97%), evaluating alendronate (n = 2), clodronate (n = 1), neridronate (n = 5), pamidronate (n = 1), and zoledronate (n = 2), were included. None. (PROSPERO: CRD42024559783)."

Journal • Retrospective data • Review • Musculoskeletal Pain • Pain

Real-world outcomes comparing zoledronic acid and denosumab in patients with metastatic breast cancer and bone metastases: A propensity score matched analysis from a global federated health research network (SABCS 2025) - "Female patients aged 18 and above with breast cancer metastatic to the bone were identified and then stratified into two groups based on treatment with zoledronic acid or pamidronate. Our study revealed that patients with breast cancer with metastatic disease to the bone who received zoledronic acid had significantly lower rates of mortality but higher occurrence of osteoporotic fracture, hypercalcemia, and pathological fracture compared to those receiving denosumab. Additional longitudinal cohort studies are imperative to explore the outcomes between these agents and inform clinical practice guidelines in these patients."

Clinical • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

Predictors of medication-related osteonecrosis of the jaw in HR+/HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors (SABCS 2025) - " A retrospective cohort of 193 female patients with HR+/HER2− mBC treated with CDK4/6i (ribociclib, palbociclib, abemaciclib) and ART (zoledronate, ibandronate, denosumab, clodronate and pamidronate) in the University Hospital Center Zagreb was analyzed with prior Ethics Committee approval. Older age and longer CDK4/6i exposure was associated with an increased risk of MRONJ in patients with HR+/HER2− mBC. Although MRONJ incidence appeared higher with abemaciclib and ribociclib compared to palbociclib, it did not reach statistical significance, possibly due to small numbers. These findings highlight the need for careful monitoring and risk assessment in patients undergoing long-term CDK4/6i therapy in combination with ART."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Real-world outcomes comparing zoledronic acid and pamidronate in patients with metastatic breast cancer with bone metastases: A propensity score matched analysis from a global federated health research network (SABCS 2025) - "Our study revealed that patients with breast cancer with metastatic disease to the bone who received zoledronic acid had significantly lower rates of mortality, osteoporotic fracture, hypercalcemia, and pathological fracture compared to those receiving pamidronate. Additional longitudinal cohort studies are imperative to explore the outcomes between these agents and inform clinical practice guidelines."

Clinical • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

Comparative efficacy of therapeutic interventions for thalassemia-induced osteoporosis: A network meta-analysis (ASH 2025) - "Compared with control, significant improvement in BMD at Total Hip or Femoral Neck (Z-score) was observed in Zoledronic Acid [MD = 0.51; 95% CI: 0.27 to 0.75], Alendronate [MD = 0.37; 95% CI: 0.20 to 0.54], Pamidronate [MD = 0.27; 95% CI: 0.01 to 0.54], and Zinc [MD = 0.26; 95% CI: 0.09 to 0.43]. It emphasizes the critical role of bisphosphonates, nutritional supplementation, and novel agents in enhancing bone health and overall quality of life for this patient population. These findings provide essential guidance for clinicians in optimizing osteoporosis management for individuals with thalassemia."

Retrospective data • Beta-Thalassemia • Genetic Disorders • Osteoporosis • Rheumatology

Optimizing skeletal health: An analysis of bone-modifying agent prescription patterns and incidence of skeletal-related events in multiple myeloma (ASH 2025) - "Afterthe diagnosis of MM, 185 patients (85.6%) were prescribed BMA (75.1% zoledronate, 11.4% denosumaband 12.4% Pamidronate). Among patientswho received BMA, 17.8% developed SREs predominantly between two to five years after the first dose,which is comparable to previous studies. Future studies may look into initiatives to improve guidelineadherence."

Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases

Management of Neonatal Severe Hyperparathyroidism due to Homozygous CASR Mutation: Challenges and Literature Insights. (PubMed, Mol Syndromol) - "Despite initial treatment with hydration and furosemide, her hypercalcemia persisted. Cinacalcet was started but failed to control calcium levels, leading to the need for a subtotal parathyroidectomy at 2.5 months of age...Postoperatively, the patient developed hypocalcemia due to hungry bone syndrome and later experienced recurrent hypercalcemia, which was managed with pamidronate followed by calcitriol...Subtotal parathyroidectomy proved essential for controlling hypercalcemia. Continued documentation of NSHPT cases will help improve treatment strategies and outcomes for this rare condition."

Journal • Endocrine Disorders • Metabolic Disorders • CASR

Treatment responses and relapse predictors in pediatric CNO: insights from a referral center. (PubMed, Rheumatology (Oxford)) - "Conventional DMARDs are effective in a limited subset of CNO patients, who may represent a milder disease phenotype. The presence of skin involvement and a greater number of affected bones may both suggest a more aggressive disease course. Anti-TNF therapies are the most effective agents, while other biologics offer promising results in resistant cases. Prospective studies are needed to guide individualized treatment strategies."

Journal • Fatigue • Inflammation • Musculoskeletal Pain • Pain • Pediatrics

Bisphosphonate-related ocular adverse events: a pharmacovigilance study based on the FAERS database. (PubMed, Endocr Connect) - "Among 6,965 ocular AE reports for five BPs (alendronate, zoledronate, pamidronate, risedronate, and ibandronate), 136 positive signals were identified, predominantly unlisted in drug labels. This study identifies high-risk and novel ocular AEs related to BPs. These findings warrant further validation in future studies."

Adverse events • Journal • Age-related Macular Degeneration • Cataract • Glaucoma • Macular Degeneration • Ocular Inflammation • Ophthalmology • Retinal Disorders

Efficacy and Safety of Varied Bisphosphonate Therapy Dosing in Patients With Hypercalcemia of Malignancy. (PubMed, JCO Oncol Pract) - "Bisphosphonates were equally efficacious in normalizing serum calcium in patients with HCM. Pamidronate 90 mg was not more efficacious than 60 mg. Rates of refractory hypocalcemia were similar."

Journal • Endocrine Disorders • Hematological Malignancies • Lung Cancer • Lymphoma • Metabolic Disorders • Multiple Myeloma • Oncology • Solid Tumor

Physicians' perspectives on the diagnosis and treatment of adult SAPHO syndrome: a cross-sectional study from China. (PubMed, Clin Rheumatol) - "While Whole body bone imaging and CT scans are widely used for the early diagnosis of adult SAPHO syndrome, there is a gap in the utilization of MRI and the practice of disease activity monitoring. Physicians prefer commonly used rheumatic drugs, but there remains limited application of bisphosphonates. Highlight • Our study first systematically investigated Chinese physicians' perspectives on the diagnosis and treatment of adult SAPHO syndrome. • We pointed out that the utilization of imaging tools (such as MRI) and bisphosphonates was low, suggesting that the diagnostic strategy needs to be optimized. • This study may aid the research of SAPHO syndrome at home and abroad, providing references."

Journal • Observational data • Dermatology • Musculoskeletal Diseases • Orthopedics • Rheumatology

Impact of Bone Modifying Agent Initiation Time, Frequency, and Duration on Skeletal-Related Events in Patients with Multiple Myeloma (ASH 2023) - "Bone modifying agents (BMA) such as denosumab or the bisphosphonates zoledronic acid and pamidronate, are used to inhibit osteoclast activity to prevent SREs. No significant association between time of BMA initiation, dosing frequency, or duration on development of SREs were observed. This suggests delaying the start time of BMAs to allow for dental clearance and initial treatment would not increase risk of SREs. Prospective trials are needed to confirm these findings."

Clinical • CNS Disorders • Hematological Malignancies • Multiple Myeloma • Musculoskeletal Diseases • Oncology • Orthopedics

Noncaseating Granulomatous Nephritis Presenting with Fanconi Syndrome (KIDNEY WEEK 2025) - "He was given Intravenous fluids and pamidronate with improvement in renal function and calcium...He was reponsive to prednisone treatment and his creatinine improved dramatically to 1.3 mg/dL. Discussion There are multiple causes of Fanconi syndrome but only 3 documented cases have been associated with sarcoidosis. The cause is thought to be from chronic interstitial nephritis leading to proximal tubular dysfunction."

Chronic Kidney Disease • Endocrine Disorders • Hematological Malignancies • Hodgkin Lymphoma • Hypotension • Immunology • Lymphoma • Metabolic Disorders • Nephrology • Renal Disease • Sarcoidosis

Recurrent Hypercalcemia in Chronic Lymphocytic Leukemia Without Transformation: A Diagnostic Trap (KIDNEY WEEK 2025) - "Case Description A 65-year-old male with relapsed CLL, CKD stage IV, and prior acalabrutinib use presented with symptomatic hypercalcemia (Ca 14.7 mg/dL) and acute kidney injury. Labs showed suppressed PTH, negative PTHrP, and high-normal vitamin D. Treated with IV fluids, pamidronate, and intranasal calcitonin...NM bone scan shows diffuse, symmetric radiotracer uptake in axial and appendicular skeleton, without focal lesions. Consistent with metabolic bone disease, not skeletal malignancy."

Acute Kidney Injury • Chronic Kidney Disease • Chronic Lymphocytic Leukemia • Endocrine Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Nephrology • Orthopedics • Renal Disease • Richter's Syndrome • Secondary Hyperparathyroidism

Beyond Averages: Informing Clinical Decision Making in the Pharmacologic Treatment of CRPS-1 using Bayesian Network Meta-Analysis (ASRA-FALL 2025) - "Across 17 trials, a total of 375 subjects were randomized to active treatment arms, and 379 to placebo. The evidence network was a placebo-anchored star (Figure 1), with edge thickness proportional to the number of trials per comparison. Treatments included: Neridronate: n=160 Ketamine: n=79 Alendronate: n=59 Pamidronate: n=48 Gabapentin: n=46 Corticosteroids: n=41 Mannitol: n=41 IVIG: n=13 Scavengers / Magnesium Sulfate: n=257 Ranked posterior probabilities of achieving a ≥20 mm VAS pain reduction, alongside average placebo-adjusted effects and 95% credible intervals, are summarized in Table 2."

Late-breaking abstract • Retrospective data • Musculoskeletal Pain

Complication Rates of Typical Hip Fractures, Subtrochanteric Femoral Fractures, and Atypical Femoral Fractures (ACR Convergence 2025) - "Those with ESRD, metabolic bone diseases other than osteoporosis, cancer, a filled prescription for etidronate, pamidronate or tiludronate or those whose dose of zoledronic acid was or < 273 days from the initial dose were excluded. The adjusted average time to complication is shorter in patients with SFF compared to THF. However, the adjusted average time to complication in patients with AFF does not differ from those with THF."

Chronic Kidney Disease • Musculoskeletal Diseases • Orthopedics • Renal Disease • Rheumatology